Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS) header
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS) profile picture

Director of Medical Services at Medipal International Hospital Clinical Physiologist NCDs • Building scalable clinical systems

Kampala
Joined March 2023
Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)Photo by Abdul M. Ssekandi, MBChB, MSc., M.A.P.S (@JC_by_AMS)
Post-hospital mobility did not improve with booklets, videos, staff training and ward posters. INTOMOB randomized 383 older adults across 12 Swiss ward clusters; the 30-day difference was 0.67 points. Low-intensity education alone may be insufficient. doi.org/10.1001/jamanetworko…
5
Before adopting an innovation, ask four questions: Does it improve a patient outcome? Compared with what? At what total cost? Can the effect be sustained in our workflow? Today’s trials show why hospitals need evidence, implementation ownership and measurement—not novelty alone.
142
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
LET US STAND WITH OUR JUNIOR COLLEAGUE, DR. KATENDE FREDRICK The Association of Anesthesiologists of Uganda (AAU) calls upon colleagues, friends, partners and the general public to support Dr. Katende Fredrick in his urgent fight against end-stage kidney disease. Our colleague urgently needs a kidney transplant, and every contribution brings him closer to receiving this life-saving treatment. Please support him through the contribution channels provided on the flyer. Every amount counts. Every act of kindness matters. Together, we can make a difference and help save a life.
1
95
2
135
2,535
Your innate genetic predisposition is exceptional; employ it to catalyze progressive advancement!
1
2
260
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
Our paper on 10 year CVD Mortality @MulagoReferral has been published in the @BMJ_Open . There is rising mortality trends and women > 50 yrs have 33% increased risk compoared to those of 30yrs. We need to pay attention to NCDs! @mulagostarr @JC_by_AMS @Tracy_Rabin @Internist_02
6
16
83
2,934
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
🤖 Made with AI
1
2
285
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
Rotos de dolor, con un nudo en la garganta y sin poder creer que esto sea verdad, desde el CD Tenerife comunicamos el trágico fallecimiento, este martes, día 3 de noviembre de 2026, a las 8:00 horas, de Jesús de Miguel Alameda. No hay palabras de consuelo; no hay absolutamente nada que mitigue este sentimiento repleto de tristeza. Estamos junto a su desolada familia, junto a sus seres queridos, junto a todo el tinerfeñismo que hoy llora por este cruel desenlace. La familia de Jesús de Miguel agradece todas y cada una de las muestras de apoyo recibidas, e igualmente solicita, de corazón, máximo respeto a su privacidad, en estos terribles momentos. 🖤 DEP
30,587
89,899
25,634
667,332
54,068,321
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
On the Lancet atlast, something about men. "Men’s poor health and premature death are not driven by biology alone, but by the environments in which they live and work." Read more ➡️ spkl.io/60177ZTP9
6
16
1,038
Circulatory shock is associated with high morbidity and mortality. Prompt identification is essential so that aggressive management can be started. Appropriate treatment is based on a good understanding of the underlying pathophysiological mechanisms. nejm.org/doi/full/10.1056/NE…
1
4
185
One journal-club exercise: read the headline, then name the actual endpoint. eGFR slope, dialysis, symptoms, hospitalisation and death answer different questions. Which outcome would change the conversation with your patient?
6
286
For an African multicentre trial, I would budget for tracing missed visits as carefully as laboratory assays. Retention determines whose outcomes we can see. Report why participants leave, not just how many remain.
2
227
A biomarker study should end with a decision worth testing. For NT-proBNP in sickle cell disease: who should receive an echo, closer follow-up or specialist review? Prediction becomes clinically useful when the next action is explicit.
1
100
Benefit within 90 days after acute HF: EMPULSE (2022) randomised 530 stabilised patients to empagliflozin or placebo. Win ratio 1.36 for death, HF events and symptoms combined. That does not mean 36% lower mortality. doi.org/10.1038/s41591-021-0…
2
143
Stroke rates: 29.14 vs 33.65 per 1,000 person-years with potassium-enriched vs regular salt. SSaSS (2021): 20,995 people in 600 randomised Chinese villages. Serious kidney disease was excluded. doi.org/10.1056/NEJMoa210567…
2
94
About 3 mmHg better 24-hour systolic BP reduction: amlodipine-based combinations beat perindopril + hydrochlorothiazide in CREOLE (2019). 728 patients randomised across 6 African countries. doi.org/10.1056/NEJMoa190111…
2
90
Slower kidney decline without diabetes: FIND-CKD (2026), 1,584 randomised adults. Finerenone improved annual eGFR slope by 0.7 mL/min/1.73m² vs placebo. Hyperkalaemia: 17.0% vs 13.3%. Monitoring remains part of the treatment. doi.org/10.1056/NEJMoa260462…
1
2
132
84% retained over 10 years: 174 of 207 Ugandan children in the NOHARM hydroxyurea programme. Ware, Opoka and colleagues (2026) report 1,861 person-years of exposure. doi.org/10.1056/NEJMc2603063
1
121